Data gathered: July 9
AI Stock Analysis - AbbVie (ABBV)
Analysis generated April 13, 2025. Powered by Chat GPT.
AbbVie, a global biopharmaceutical company, was spun off from Abbott Laboratories in 2013. The company specializes in developing and marketing advanced therapies that address some of the greatest health challenges today. AbbVie's primary focus areas include immunology, oncology, virology, and neuroscience. With a diversified portfolio of drugs, including blockbuster products like Humira, AbbVie has positioned itself as a formidable entity in the pharmaceutical industry.
Stock Alerts - AbbVie (ABBV)
 |
AbbVie | July 8 News Alert: AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune Pipeline |
|
AbbVie | July 1 News Alert: AbbVie to Acquire Capstan Therapeutics, Further Strengthening Commitment to Transforming Patient Care in Immunology |
|
AbbVie | June 12 Josh Gottheimer (member of U.S. congress) is buying shares |
|
AbbVie | June 10 Rob Bresnahan (member of U.S. congress) is buying shares |
Download our app to get future alerts delivered in real-time.
Alternative Data for AbbVie
About AbbVie
AbbVie Inc is a biopharmaceutical company that discovers, develops, manufactures and sells a range of pharmaceutical products for treating chronic autoimmune diseases, virology and neurological disorders.
| Price | $189.77 |
| Target Price | Sign up |
| Volume | 5,340,000 |
| Market Cap | $334B |
| Year Range | $161.92 - $214.67 |
| Dividend Yield | 3.53% |
| PE Ratio | 79.84 |
| Analyst Rating | 71% buy |
| Earnings Date | July 31 '25 |
| Industry | Drug Manufacturers |
In the news
 |
AbbVie Inc. (NYSE:ABBV) Receives $211.29 Consensus PT from AnalystsJuly 9 - ETF Daily News |
|
Leerink Partnrs Has Positive View of AbbVie FY2026 EarningsJuly 8 - ETF Daily News |
Nocturia Market Research and Forecast Report 2025-2034, Featuring Leading Players - Urigen Pharmaceuticals, Glenmark Pharmaceuticals, AbbVie, Teva PharmaceuticalsJuly 8 - GlobeNewswire |
|
 |
AbbVie to Acquire Capstan Therapeutics for $2.1B, Boosting Autoimmune PipelineJuly 8 - Yahoo Entertainment |
 |
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?July 7 - Yahoo |
 |
Here's What to Expect From AbbVie's Next Earnings ReportJuly 7 - Barchart.com |
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q1 '25 | 13.3B | 4B | 11.2B | 1.29B | 3.73B | 2.460 |
| Q4 '24 | 15.1B | 10.5B | 10.7B | -22M | 566M | 2.160 |
| Q3 '24 | 14.5B | 4.21B | 10.2B | 1.56B | 4.93B | 3.000 |
| Q2 '24 | 14.5B | 2.18B | 12.3B | 1.37B | 7.13B | 2.650 |
| Q1 '24 | 12.3B | 4.08B | 8.23B | 1.37B | 5.56B | 2.310 |
Insider Transactions View All
| Stewart Jeffrey Ryan filed to sell 86,366 shares at $209.5. April 2 '25 |
| Stewart Jeffrey Ryan filed to sell 53,234 shares at $210.5. April 2 '25 |
| Reents Scott T filed to sell 11,577 shares at $212.3. March 18 '25 |
| RICHMOND TIMOTHY J. filed to sell 6,130 shares at $211.3. March 4 '25 |
| GONZALEZ RICHARD A filed to sell 388,929 shares at $210.5. March 4 '25 |
Similar companies
| Company | Price | AI Score | |
|---|---|---|---|
 |
Johnson & JohnsonJNJ |
$155.79 0% | 38 |
 |
Eli Lilly and CompanyLLY |
$777.66 0% | 67 |
 |
PfizerPFE |
$25.62 0% | 59 |
 |
AstrazenecaAZN |
$70.02 0% | 49 |
 |
TherapeuticsMDTXMD |
$1.18 0% | 44 |
Congress Trading View All
| Politician | Filing Date | Type | Size |
|---|---|---|---|
| Josh Gottheimer |
Jun 12, 25 | Buy | $1K - $15K |
| Rob Bresnahan |
Jun 10, 25 | Buy | $1K - $15K |
| Josh Gottheimer |
May 14, 25 | Buy | $1K - $15K |
Read more about AbbVie (ABBV) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, instagram followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of AbbVie?
The Market Cap of AbbVie is $334B.
What is AbbVie's PE Ratio?
As of today, AbbVie's PE (Price to Earnings) ratio is 79.84.
When does AbbVie report earnings?
AbbVie will report its next earnings on July 31 '25.
What is the current stock price of AbbVie?
Currently, the price of one share of AbbVie stock is $189.77.
How can I analyze the ABBV stock price chart for investment decisions?
The ABBV stock price chart above provides a comprehensive visual representation of AbbVie's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling AbbVie shares. Our platform offers an up-to-date ABBV stock price chart, along with technical data analysis and alternative data insights.
Does ABBV offer dividends to its shareholders?
Yes, AbbVie (ABBV) offers dividends to its shareholders, with a dividend yield of 3.53%. This dividend yield represents AbbVie's commitment to providing value to its shareholders through both potential capital appreciation and steady income. Investors considering AbbVie in their portfolio should factor in this dividend policy alongside the company's growth prospects and market position.
What are some of the similar stocks of AbbVie?
Some of the similar stocks of AbbVie are Johnson & Johnson, Eli Lilly and Company, Pfizer, Astrazeneca, and TherapeuticsMD.
.